HEALTHCARE
Oncology Fast Facts
Season 1
About This Season
Season 1 of Fast Facts Oncology is an eight-part special that focuses on breast cancer and updates from ESMO 2022. Topics include issues pertinent to low- and middle-income countries, the changing treatment landscape of breast cancer, and the latest updates from ESMO 2022. We are joined by experts Dr Vinicius Goncalves, Dr Shaheenah Dawood, Dr Omar Hamid and Abeda Steenkamp from the Cancer Association of South Africa.
All Episodes
Episode 8 - Dr Hope Rugo – ESMO 2022 – Exploring the Latest Trial Data and Advances in Breast Cancer Treatments
Welcome to the third episode in a three-part special live from ESMO 2022. In this episode focused on breast cancer we speak with Dr Hope Rugo, Director of Breast Oncology and Clinical Trials Education at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. Dr Rugo summarizes the TROPICS02 trial that she presented at this year's conference. We also discuss how data presented from the METEORA and ICON trials add to clinical understandings of immunotherapy response. Coverage is also provided to the ADAPT trial. Finally, we discuss how these clinical improvements in response and progression free survival (PFS) translate to the patient experience.
This podcast episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode.
In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.
Episode 7 - Dr Shaheenah Dawood – ESMO 2022 – Clinical Trial Updates in Breast Cancer Management
Welcome to the second episode in a three-part special live from ESMO 2022. In this episode focused on breast cancer, we speak with Dr Shaheenah Dawood, a practicing medical oncologist from Dubai, United Arab Emirates. Dr Dawood discusses the MONARCH3 trial – its background, recent findings and how it differs from the MONARCHER trial. Coverage is also given to the presentations on oral selective estrogen receptor downregulators (SERDs) as a treatment option for breast cancer patients.
This podcast episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode.
In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.
Episode 6 - Dr Chetan Deshmukh – ESMO 2022 – The Latest Updates in Colorectal Cancer
Welcome to the first episode in a three-part special live from ESMO 2022. In this episode focused on colorectal cancer, we speak with Dr Chetan Deshmukh, a practicing medical oncologist from Pune, India. Dr Deshmukh discusses the results from the CARIO5 study which have been presented at the congress. He also shares with us his thoughts on the promise of novel immunotherapeutics and targeted therapies in CRC management and provides his perspective on disparities in drug access in low-middle income countries.
This podcast episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice.
The viewers assume all risk for use of the information and the content provided in the podcast episode. In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.
Episode 5 - Breast Cancer Awareness with Abeda Steenkamp from CANSA
The fifth and final episode of our special series on breast cancer for Karger’s Fast Facts Oncology Podcast. In episode we are joined by Abeda Steenkamp, breast cancer survivor and Service Coordinator for the Cancer Association of South Africa. Join us as we talk about stigma and taboos surrounding breast cancer in South Africa (CANSA). Furthermore, Abeda Kindly shares her own experiences as a breast cancer patient, discusses the important role of education and support, and gives an insight into her work and tasks as a Service Coordinator for CANSA. To accompany this series on breast cancer, Karger have produced a summary sheet showcasing the breast cancer highlights from this year’s ASCO 2022 meeting.
This episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode.
In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.
Supplementary Material
Episode 4 - Are Advances in Breast Cancer Treatment Really a Boon for Patients with Dr Omar
The fourth episode in a five-part special on breast cancer for Karger’s Fast Facts Oncology Podcast. In this episode we are joined by Dr Omar Hamid from Nairobi Kenya. Dr Omar is a clinical oncologist and passionate advocate for affordable cancer care. Listen in as we discuss whether advances in breast cancer treatment are really a boon for patients. To accompany this series on breast cancer, Karger have produced a summary sheet showcasing the breast cancer highlights from this year’s ASCO 2022 meeting.
This episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode.
In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.
Episode 3 - Part 2: Changing Landscape in Managing Breast Cancer Patients with Dr Dawood
The third episode in a five-part special on breast cancer for Karger’s Fast Facts Oncology Podcast. In this episode we are again joined by Dr Shaheenah Dawood, a consultant medical oncologist and professor in clinical oncology from the United Arab Emirates, for the second part of our discussion on the ‘changing landscape in managing breast cancer patients’. To accompany this series on breast cancer, Karger have produced a summary sheet showcasing the breast cancer highlights from this year’s ASCO 2022 meeting.
This episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode.
In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.
Episode 2 - Part 1: Changing Landscape in Managing Breast Cancer Patients with Dr Dawood
The second episode in a five-part special on breast cancer for Karger’s Fast Facts Oncology Podcast. In this episode we are joined by Dr Shaheenah Dawood, a consultant medical oncologist and professor in clinical oncology from the United Arab Emirates, to discuss the changing landscape in managing breast cancer patients. To accompany this series on breast cancer, Karger have produced a summary sheet showcasing the breast cancer highlights from this year’s ASCO 2022 meeting.
This episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode.
In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.
Episode 1 - Penetration of Breast Cancer Screening in LMICs with Dr Goncalves
The first episode in a five-part special on breast cancer for Karger’s Fast Facts Oncology Podcast. In this episode we are joined by Dr Vinicius Knackfuss Gonçalves from the Hospital São Lucas da PUCRS, in Porto Alegre, Brazil to discuss the topic of penetration of breast cancer screening in low middle income countries. To accompany this series on breast cancer, Karger have produced a summary sheet showcasing the breast cancer highlights from this year’s ASCO 2022 meeting.
This episode has been made possible by the contribution from Mylan Pharmaceuticals Private Limited, a Viatris Company. Viatris did not have any influence on the content and all items were subject to independent editorial review. These contents should not be construed to be medical, or consulting advice. The viewers assume all risk for use of the information and the content provided in the podcast episode.
In no event shall Mylan Pharmaceuticals Private Limited or any of its affiliates, directors, employees, officers, consultants and service providers be liable for, directly or indirectly, any damages of any kind or nature, including without limitation, direct, indirect, incidental, consequential, or any claims or losses, whether foreseeable or not; or whether the user has been informed of the possibility in advance, resulting from or in connection with the creation or use of or reliance in the podcast episode.
About the Speakers
Dr Vinicius Knackfuss Gonçalves
Dr Vinicius Knackfuss Gonçalves is a medical oncologist from Brazil. Having trained at the Federal University of Health Sciences Foundation of Porto Alegre, he currently practices at the Hospital São Lucas da PUCRS, in Porto Alegre Brazil.
Abeda Steenkamp
Abeda Steenkamp is a breast cancer survivor and Service Coordinator for the Cancer Association of South Africa (CANSA).
Dr Omar
Dr Omar is a Clinical Oncologist from Nairobi, Kenya. His main areas of interest are lung cancer, gastrointestinal cancers, genitourinary cancers and breast cancer. He is passionate about cancer care in low- and middle-income countries, particularly cancer awareness and patient education. Dr Omar has a keen interest in cancer research, clinical-trials, cancer biology, radiation biology, cancer genomics, targeted therapy and Immuno-oncology. He is also a resident faculty member and tumour board panellist at the international cancer institute in Eldoret, Kenya and practices at the Garissa Cancer Center, Kenya.
Dr Shaheenah Dawood
Dr Shaheenah Dawood is a consultant medical oncologist and professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple Scholar-in-Training Awards and ASCO Merit Awards. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the Excellence in Oncology Care summit that is held annually in Dubai and is co-president of the Asia-Pacific Breast Cancer Summit (APBCS) and Asia-Pacific Gastroenterology Cancer Summit (APGCS).
Chetan Deshmukh
Dr Chetan Deshmukh is a practicing medical oncologist and clinical researcher at the Deenanath Mangeshkar Hospital & Research Center in the city of Pune, India. He received his training in medical oncology from the Tata Memorial Hospital in Mumbai. Dr Deshmukh has participated as a principle investigator in over 75 clinical trials.
Hope Rugo
Dr Hope S. Rugo, MD, FASCO, is professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, where she is also the director of Breast Oncology and Clinical Trials Education. Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at University of California San Francisco in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.
